Since both studies were conducted under similar protocols, data from both were combined and reported jointly
The useful question is no longer only how many scripts were supplied? It is: Which patients can access treatment, through which pathway, for which indication, at what cost, with what persistence, and with what outcome
In my previous article I assumed a $10,000 starting value ( view my blog discussion here )
Published research on BPC-157 is indexed on PubMed
Altered gut motility : GLP-1 agonists influence the entire gastrointestinal tract, potentially affecting digestive processes
2 stallions, 13 geldings, 9 mares) competing in the south of Spain (Winter Sunshine Tour) during 5 weeks (34 days/week), were used in the present study